Zacks Investment Research cut shares of Corindus Vascular Robotics (NYSEAMERICAN:CVRS) from a buy rating to a hold rating in a report released on Friday.

According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “

CVRS has been the topic of several other research reports. ValuEngine cut Corindus Vascular Robotics from a hold rating to a sell rating in a research note on Tuesday, October 3rd. BidaskClub cut Corindus Vascular Robotics from a sell rating to a strong sell rating in a research note on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $2.33.

Shares of Corindus Vascular Robotics (CVRS) traded down $0.02 on Friday, hitting $1.03. The company’s stock had a trading volume of 212,712 shares, compared to its average volume of 524,839. The firm has a market capitalization of $194.36, a PE ratio of -4.29 and a beta of 19.49. Corindus Vascular Robotics has a 12 month low of $0.40 and a 12 month high of $2.25.

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) last issued its quarterly earnings data on Tuesday, November 7th. The medical equipment provider reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. The company had revenue of $2.43 million for the quarter, compared to analysts’ expectations of $3.60 million. Corindus Vascular Robotics had a negative return on equity of 110.93% and a negative net margin of 323.84%.

Several large investors have recently added to or reduced their stakes in CVRS. Goldman Sachs Group Inc. increased its holdings in Corindus Vascular Robotics by 147.8% in the second quarter. Goldman Sachs Group Inc. now owns 58,824 shares of the medical equipment provider’s stock valued at $109,000 after buying an additional 35,086 shares during the last quarter. Rhumbline Advisers increased its holdings in Corindus Vascular Robotics by 67.6% in the second quarter. Rhumbline Advisers now owns 80,868 shares of the medical equipment provider’s stock valued at $150,000 after buying an additional 32,608 shares during the last quarter. New York State Common Retirement Fund increased its holdings in Corindus Vascular Robotics by 334.6% in the second quarter. New York State Common Retirement Fund now owns 89,100 shares of the medical equipment provider’s stock valued at $166,000 after buying an additional 68,599 shares during the last quarter. California State Teachers Retirement System increased its holdings in Corindus Vascular Robotics by 34.4% in the second quarter. California State Teachers Retirement System now owns 148,558 shares of the medical equipment provider’s stock valued at $276,000 after buying an additional 38,000 shares during the last quarter. Finally, Teachers Advisors LLC increased its holdings in Corindus Vascular Robotics by 184.7% in the second quarter. Teachers Advisors LLC now owns 167,633 shares of the medical equipment provider’s stock valued at $312,000 after buying an additional 108,745 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.watchlistnews.com/corindus-vascular-robotics-cvrs-downgraded-by-zacks-investment-research/1806144.html.

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Get a free copy of the Zacks research report on Corindus Vascular Robotics (CVRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corindus Vascular Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics and related companies with Analyst Ratings Network's FREE daily email newsletter.